Interleukin-6 inhibitors in non-COVID-19 ARDS: analyzing the past to step into the post-COVID-19 era
Crit Care
.
2023 Mar 25;27(1):124.
doi: 10.1186/s13054-023-04394-w.
Authors
Lucia Gandini
#
1
2
3
,
Gabriele Fior
#
1
2
4
,
Andreas Schibler
1
2
4
,
Nchafatso G Obonyo
1
2
5
6
,
Gianluigi Li Bassi
1
2
4
,
Jacky Y Suen
7
8
,
John F Fraser
9
10
11
Affiliations
1
Critical Care Research Group, The Prince Charles Hospital, University of Queensland, Brisbane, QLD, Australia.
2
Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia.
3
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
4
Intensive Care Unit, St. Andrews War Memorial Hospital, Brisbane, QLD, Australia.
5
Wellcome Trust Centre for Global Health Research, Imperial College London, London, UK.
6
Initiative to Develop African Research Leaders (IDeAL)/KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
7
Critical Care Research Group, The Prince Charles Hospital, University of Queensland, Brisbane, QLD, Australia. j.suen1@uq.edu.au.
8
Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia. j.suen1@uq.edu.au.
9
Critical Care Research Group, The Prince Charles Hospital, University of Queensland, Brisbane, QLD, Australia. fraserjohn001@gmail.com.
10
Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia. fraserjohn001@gmail.com.
11
Intensive Care Unit, St. Andrews War Memorial Hospital, Brisbane, QLD, Australia. fraserjohn001@gmail.com.
#
Contributed equally.
PMID:
36966340
PMCID:
PMC10039681
DOI:
10.1186/s13054-023-04394-w
No abstract available
Publication types
Letter
MeSH terms
COVID-19*
Humans
Interleukin-6 Inhibitors
Respiratory Distress Syndrome* / drug therapy
Substances
Interleukin-6 Inhibitors